Muscular Dystrophy—Reason for Optimism?
نویسندگان
چکیده
منابع مشابه
Muscular Dystrophy—Reason for Optimism?
Characterization of the mechanisms underlying various types of muscular dystrophy has been an outstanding triumph of molecular biology. Increasing clarification of the aberrant cellular processes responsible for these conditions may ultimately permit the development of effective means for molecular intervention, allowing correction of the abnormal cellular physiology that results in the dystrop...
متن کاملOptimism for Boosting Concurrency
Modern concurrent programming benefits from a large variety of synchronization techniques. These include conventional pessimistic locking, as well as optimistic techniques based on conditional synchronization primitives or transactional memory. Yet, it is unclear which of these approaches better leverage the concurrency inherent to multi-cores. In this paper, we compare the level of concurrency...
متن کاملReasons for Cautious Optimism
Luis G. Melo, Alok S. Pachori, Deling Kong, Massimiliano Gnecchi, Kai Wang, Richard E. Myocardium : Reasons for Cautious Optimism Molecular and Cell-Based Therapies for Protection, Rescue, and Repair of Ischemic Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2004 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Aven...
متن کاملOptimism.
Optimism is an individual difference variable that reflects the extent to which people hold generalized favorable expectancies for their future. Higher levels of optimism have been related prospectively to better subjective well-being in times of adversity or difficulty (i.e., controlling for previous well-being). Consistent with such findings, optimism has been linked to higher levels of engag...
متن کاملImmunotherapies: cause for measured optimism.
exciting potential that the field of immunotherapeutics offers for human health and economic reward was show-cased at the first European Therapeutic Vaccine Congress (27–28 June 2002; London, UK). Data from 19 ongoing or recently completed Phase I–III clinical trials were presented by 11 biotechnology companies and one academic group. Conspicuous by their absence were clinical presentations fro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell
سال: 2002
ISSN: 0092-8674
DOI: 10.1016/s0092-8674(01)00626-2